Our Knowledge Hub: Articles & Events

Biosimilars of Rituximab grab 50% market share in top EU markets after less than 2 years.

Oncology products will represent more than 20% of the German drug market. Can the system support it?

Parallel trading get 30% of branded products to Big Pharma in German market after patent expiration.

Notes on the German generics and biosimilars market 2016-2018.

Management (specific?) skills to succeed in pharmaceutical emerging markets.

8 common mistakes pharmaceutical companies make when addressing European Markets.

Why Europe Generic Companies Should Fear Indian Companies (this time). Lessons for Newcomers.